# Impact of High-Dose Cefepime During the Initial 48 h on Intensive Care Unit Survival in Sepsis: A Retrospective Observational Study

**Authors:** Tsukasa Kuwana, Kosaku Kinoshita, Yuma Kanai, Yurina Yamaya, Ken Takahashi, Satoshi Ishizuka, Toru Imai

PMC · DOI: 10.3390/antibiotics15010088 · Antibiotics · 2026-01-15

## TL;DR

High-dose cefepime given in the first 48 hours may improve survival in ICU patients with sepsis, regardless of kidney function.

## Contribution

Demonstrates high-dose cefepime improves ICU survival in sepsis patients, independent of renal function.

## Key findings

- High-dose cefepime was significantly associated with improved ICU survival (OR 5.43, p = 0.0066).
- Results remained consistent across different inverse probability of treatment weighting models.
- Findings suggest benefit of high-dose cefepime in sepsis patients regardless of kidney function.

## Abstract

Background/Objectives: Sepsis is a life-threatening condition associated with high mortality. Optimal dosing strategies for β-lactam antibiotics in sepsis remain controversial, particularly in patients with renal impairment. Cefepime (CFPM) is widely used as empiric therapy; however, its appropriate initial dosing in critically ill patients is unclear. This study aimed to evaluate whether high-dose CFPM administration during the first 48 h improves survival in patients with sepsis, irrespective of renal function. Methods: This single-center, retrospective, observational study included adult intensive care unit (ICU) patients with sepsis who received CFPM as initial therapy between January 2017 and December 2024. Patients were categorized into High-dose (12 g within 48 h; 2 g every 8 h) and Low-dose (<12 g/48 h) groups. The primary outcome was ICU survival. To address confounding, inverse probability of treatment weighting (IPTW) based on serum creatinine was applied, with sensitivity analyses using 1% trimmed and stabilized IPTW. Results: Of 122 eligible patients, 84 were analyzed (High-dose: n = 27; Low-dose: n = 57). After IPTW adjustment, high-dose CFPM was significantly associated with improved ICU survival (odds ratio [OR] 5.43, 95% confidence interval [CI] 1.60–18.39, p = 0.0066). This association remained consistent in the 1% trimmed IPTW analysis (OR 4.07, 95% CI 1.19–13.97, p = 0.0256). Stabilized IPTW yielded a similar effect estimate, though without statistical significance (OR 5.43, 95% CI 0.72–41.16, p = 0.1017). Overall, results were consistent in direction and magnitude across models. Conclusions: High-dose CFPM administration during the initial 48 h was associated with improved ICU survival in patients with sepsis, independent of renal function.

## Linked entities

- **Chemicals:** Cefepime (PubChem CID 5479537), CFPM (PubChem CID 5479537)

## Full-text entities

- **Diseases:** Sepsis (MESH:D018805), critically ill (MESH:D016638), renal impairment (MESH:D007674)
- **Chemicals:** beta-lactam (MESH:D047090), CFPM (MESH:D000077723), creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12837887/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12837887/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12837887/full.md

---
Source: https://tomesphere.com/paper/PMC12837887